Antibodies to watch in 2022

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

(2021) Feng-Hua Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.

(2021) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

(2021) Yuankai Shi et al.   Journal of Hematology & Oncology

Antibodies to watch in 2021

(2021) Hélène Kaplon et al.   mAbs

Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model

(2021) Floriana Cremasco et al.   PLoS One

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

(2021) Cheolmin Kim et al.   Nature Communications

FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma

(2021) U. Sahin et al.   ANNALS OF ONCOLOGY

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

(2021) Kristian Reich et al.   LANCET

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

(2021) Kenneth B Gordon et al.   LANCET

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells

(2021) David J. DiLillo et al.   Blood Advances

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

(2021) Joost Neijssen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

(2021) Martin Hutchings et al.   JOURNAL OF CLINICAL ONCOLOGY

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

(2021) Paolo F Caimi et al.   LANCET ONCOLOGY

FDA approves 100th monoclonal antibody product

(2021) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Sutimlimab in Cold Agglutinin Disease

(2021) Alexander Röth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bimekizumab versus Adalimumab in Plaque Psoriasis

(2021) Richard B. Warren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bimekizumab versus Secukinumab in Plaque Psoriasis

(2021) Kristian Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma

(2021) Andrew Menzies-Gow et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare

(2021) Siew Eng Choon et al.   BMJ Open

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

(2021) Jie Wang et al.   JAMA Oncology

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant

(2021) Dong-Kyun Ryu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Generalized Pustular Psoriasis: Divergence of Innate and Adaptive Immunity

(2021) Dominik Samotij et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.

(2021) Shukui Qin et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of KN046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer.

(2021) Yunpeng Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL).

(2021) L Elizabeth Budde et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL).

(2021) Yuqin Song et al.   JOURNAL OF CLINICAL ONCOLOGY

Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.

(2021) David M. O'Malley et al.   JOURNAL OF CLINICAL ONCOLOGY

RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.

(2021) Lin Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

(2021) Jesus G. Berdeja et al.   JOURNAL OF CLINICAL ONCOLOGY

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

(2021) Evan J. Lipson et al.   JOURNAL OF CLINICAL ONCOLOGY

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

(2021) Jian Li et al.   Journal of Hematology & Oncology

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

(2021) Saad Z Usmani et al.   LANCET

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

(2021) Hai-Qiang Mai et al.   NATURE MEDICINE

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

(2021) Stephen Salloway et al.   NATURE MEDICINE

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

(2021) Michael Dougan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

(2021) Anil Gupta et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.

(2020) Zhi Peng et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11)

(2020) Yunpeng Yang et al.   Journal of Thoracic Oncology

1419TiP ARC-7: A phase II study to evaluate the safety and efficacy of zimberelimab alone, AB154 in combination with zimberelimab, and AB154 in combination with zimberelimab and AB928 in front-line, PD-L1 expressing, non-small cell lung cancer (NSCLC)

(2020) A. Chaudhry et al.   ANNALS OF ONCOLOGY

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

(2020) Dingwei Ye et al.   CANCER SCIENCE

A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II

(2020) Torayuki Okuyama et al.   MOLECULAR THERAPY

Sintilimab: A Promising Anti-Tumor PD-1 Antibody

(2020) Lin Zhang et al.   Frontiers in Oncology

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

(2019) Eric L. Smith et al.   Science Translational Medicine

Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma

(2019) Bertil E. Damato et al.   Cancers

Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development

(2019) Christophe Dumet et al.   mAbs

TIGIT as an emerging immune checkpoint

(2019) H. Harjunpää et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin’s lymphoma

(2016) Lin Gui et al.   Chinese Journal of Cancer Research

Antibodies to watch in 2010

(2010) Janice M. Reichert   mAbs